In addition to clinical and educational duties, our Hospitalists are active in the research community and we promote discoveries through innovative research and technology. Our focus areas include; inpatient hospital care, quality improvement and medical education.
Our faculty conduct research at Stanford University and Stanford Tri-Valley and we are currently recruiting for clinical trials as part of the global response to COVID-19.
Clinical Trial Information
A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults
Conducting a randomized, double-blind, placebo-controlled phase 3 trial to evaluate the safety and efficacy of interferon beta-1a and remdesivir compared to remdesivir alone in hospitalized adult patients diagnosed with COVID-19. The study is sponsored by the National Institutes of Health and is a multicenter trial that will be conducted at as many as 100 sites globally.
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate The Safety And Efficacy of Tocilizumab in Patients with Severe COVID-19 Pneumonia
Conducting a randomized, double-blind, placebo-controlled phase 3 trial to evaluate the safety and efficacy of tocilizumab, an interleukin-6 receptor antibody, in hospitalized adult patients diagnosed with severe COVID-19 pneumonia. This multicenter trial is being conducted at 65 sites globally.
The Division of Hospital Medicine are actively involved in academic pursuits and publish in numerous prominent journals. We invite you to read more about our research below.